Literature DB >> 10921397

Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C.

M Omata1, Y Shiratori.   

Abstract

Chronic hepatitis C is a common disease that slowly progresses to cirrhosis and eventually to hepatocellular carcinoma (HCC). Histology offers an important insight into disease prognosis and treatment response. Biochemical and virological responses to interferon (IFN) therapy are associated with an improvement in liver histology during and shortly after treatment, but the impact of treatment on the history of a slowly progressive disease cannot be ascertained by evaluating results at the completion of treatment. Some recent studies showed that the severity of hepatic inflammation may be a major factor driving progression of chronic hepatitis C to cirrhosis, and that improving hepatic inflammation may be associated with regression or retardation of fibrosis, especially in patients with virological sustained response. Many recent studies have shown an inhibition of the development of decompensation and HCC after IFN therapy, but a randomized controlled study using a large number of subjects with a more than 5-year observation period will be required to elucidate the exact role of antiviral therapy for the delay of decompensation or suppression of HCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10921397     DOI: 10.1046/j.1440-1746.2000.02115.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  6 in total

1.  Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease.

Authors:  Yukiko Saitou; Katsuya Shiraki; Yutaka Yamanaka; Yumi Yamaguchi; Tomoyuki Kawakita; Norihiko Yamamoto; Kazushi Sugimoto; Kazumoto Murata; Takeshi Nakano
Journal:  World J Gastroenterol       Date:  2005-01-28       Impact factor: 5.742

2.  Patients' preferences for treatment of hepatitis C.

Authors:  Liana Fraenkel; Diane Chodkowski; Joseph Lim; Guadalupe Garcia-Tsao
Journal:  Med Decis Making       Date:  2009-07-27       Impact factor: 2.583

3.  Hepatitis C: current options for nonresponders to peginterferon and ribavirin.

Authors:  Emmanuel Thomas; Michael W Fried
Journal:  Curr Gastroenterol Rep       Date:  2008-02

4.  Interferon-beta reduces the mouse liver fibrosis induced by repeated administration of concanavalin A via the direct and indirect effects.

Authors:  Junichi Tanabe; Akiko Izawa; Natsumi Takemi; Yasushi Miyauchi; Yuichi Torii; Hiromi Tsuchiyama; Tomohiko Suzuki; Saburo Sone; Kazuki Ando
Journal:  Immunology       Date:  2007-07-20       Impact factor: 7.397

5.  Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis.

Authors:  Yoon Seok Roh; Surim Park; Jong Won Kim; Chae Woong Lim; Ekihiro Seki; Bumseok Kim
Journal:  Hepatology       Date:  2014-05-27       Impact factor: 17.425

Review 6.  Early liver cancer: concepts, diagnosis, and management.

Authors:  Hideo Yoshida; Haruhiko Yoshida; Shuichiro Shiina; Masao Omata
Journal:  Int J Clin Oncol       Date:  2005-12       Impact factor: 3.850

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.